3Plosker GL,Lyseng-Williamson A.Buprenorphine 5, 10 and 20 mug/h transdermal patch: a guide to its use in chronic non-malignant pain.CNS Drugs.2012;26(4):367-373.
4Al-Tawil N,Odar-Cederlof I,Berggren AC,et al. Pharmacokinetics of transdermal buprenorphine patch in the elderly.Eur J Clin Pharm.2013;69(2):143-149.
6Karlsson J,Soderstrom A,Augustini BG, et al.ls buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study.Curr Med Res Opin.2014;30(4): 575-587.
7Schutter U,Ritzdorf I,Heckes B.The transdermal 7-day buprenorphine patch-an effective and safe treatment option, if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional study.MMW Fortschr Med.2010;152(31-33) :49.
8Gordon A,Callaghan D,Spink D,et al.Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study followed by an open-label extension phase.Clin Ther.2010; 32(5):844-860.
9Plosker GL.Buprenorphine 5, 10 and 20 mug/h transdermal patch: a review of its use in the management of chronic non-malignant pain. Drugs.2011 ;71 (18):2491-2509.
10Uberall MA,Muller-Schwefe GH.Long-term treatment of chronic pain with low-dose 7-day buprenorphine transdermal patch. Observational data from elderly patients of pain relief and quality of life.MMW Fortschr Med.2013;155 Suppl 3: 87-96.
